The Correlation between Increased Serum Concentrations of Interleukin-6 Family Cytokines and Disease Activity in Rheumatoid Arthritis Patients

키워드

참고문헌 (32)

1. Hochberg MC, "Rheumatology. In Classification and epidemiology. 4th ed", pp.755~762 (2008), Mosby
2. McInnes IB, "Cytokines in the pathogenesis of rheumatoid arthritis", Nat Rev Immunol, 7, pp.429~442 (2007)
3. Brennan F, "Update on cytokines in rheumatoid arthritis", Curr Opin Rheumatol, 19, pp.296~301 (2007)
4. Szekanecz Z, "Macrophages and their products in rheumatoid arthritis", Curr Opin Rheumatol, 19, pp.289~295 (2007)
5. Huber LC, "Synovial fibroblasts: key players in rheumatoid arthritis", Rheumatology, 45, pp.669~675 (2006)
6. Nishimoto N, "Interleukin 6: from bench to bedside", Nat Clin Pract Rheumatol, 2, pp.619~626 (2006)
7. Madhok R, "Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity", Ann Rheum Dis, 52, pp.232~234 (1993)
8. Knudsen LS, "Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis", Biomarkers, 13, pp.59~78 (2008)
9. Smolen JS, "Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial", Lancet, 371, pp.987~997 (2008)
10. Genovese MC, "Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study", Arthritis Rheum, 58, pp.2968~2980 (2008)
11. Emery P, "van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial", Ann Rheum Dis, 67, pp.1516~1523 (2008)
12. Kishimoto T, "Interleukin-6 family of cytokines and gp130", Blood, 86, pp.1243~1254 (1995)
13. Wong PK, "The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover", Arthritis Rheum, 48, pp.1177~1189 (2003)
14. Okamoto H, "The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis", Arthritis Rheum, 40, pp.1096~1105 (1997)
15. Robak T, "Serum levels of inter leukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis", Mediators Inflamm, 7, pp.347~353 (1998)
16. Waring PM, "Increased levels of leukemia inhibitory factor in synovial fluid from patients with rheumatoid arthritis and other inflammatory arthritides", Arthritis Rheum, 36, pp.911~915 (1993)
17. Arnett FC, "Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis", Arthritis Rheum, 31, pp.315~324 (1988)
18. Prevoo ML, "Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis", Arthritis Rheum, 38, pp.44~48 (1995)
19. Smolen JS, "Activity assessments in rheumatoid arthritis", Curr Opin Rheumatol, 20, pp.306~313 (2008)
20. Zatarain E, "Monitoring disease activity of rheumatoid arthritis in clinical practice: contributions from clinical trials", Nat Clin Pract Rheumatol, 2, pp.611~618 (2006)
21. Hermann JA, "Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis", Arthritis Rheum, 41, pp.1388~1397 (1998)
22. Walmsley M, "An anti-inflammatory role for interleukin-11 in established murine collagen-induced arthritis", Immunology, 95, pp.31~37 (1998)
23. Moreland L, "Results of a phase-I", II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis, 2001, pp.3, 247~252
24. Carroll GJ, "Leukaemia inhibitory factor stimulates proteoglycan resorption in porcine articular cartilage", Rheumatol Int, 13, pp.5~8 (1993)
25. Campbell IK, "Production of leukemia inhibitory factor by human articular chondrocytes and cartilage in response to interleukin-1 and tumor necrosis factor alpha", Arthritis Rheum, 36, pp.790~794 (1993)
26. Straub RH, "Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs", Br J Rheumatol, 36, pp.1298~1303 (1997)
27. Kopf M, "Impaired immune and acute-phase responses in interleukin-6-deficient mice", Nature, 368, pp.339~342 (1994)
28. Sasai M, "Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice", Arthritis Rheum, 42, pp.1635~1643 (1999)
29. Xing Z, "IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses", J Clin Invest, 101, pp.311~320 (1998)
30. Cronstein BN, "Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis", Bull NYU Hosp Jt Dis, 65(Suppl 1), pp.S11~S15 (2007)
31. Yin TG, "Enhancement of in vitro and in vivo antigen-specific antibody responses by interleukin 11", J Exp Med, 175, pp.211~216 (1992)
32. Trepicchio WL, "Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production", J Immunol, 157, pp.3627~3634 (1996)

관련 논문AI추천